Orexo

Orexo: A Leading Integrated Pharmaceutical Company in the Development of Improved Medicines and Digital TherapiesOrexo AB is a leading integrated pharmaceutical company specializing in the development of improved medicines and digital therapies. Established in 1995, the company is headquartered in Uppsala, Sweden. It was listed on the Stockholm Stock Exchange in 2005 under the ticker symbol ORX and later went public in the United States through American Depositary Receipts (ADRs). The company focuses on developing new drugs and researching innovative drug delivery technologies for addiction-related diseases such as Opioid Use Disorder (OUD) to help patients manage drug addiction (a chronic condition that affects an individual's brain and behavior; people with drug addiction are more likely to suffer from other mental illnesses, and vice versa). Orexo DTx currently has three products under development: vorvida® for alcohol abuse, deprexis® for depression, and modia™ for Opioid Use Disorder (OUD). These digital products will be commercialized globally by Orexo DTx, with the United States being its primary market. The company’s goals and strategies for 2020 and beyond include continuing to expand and promote its pharmaceutical business while innovating in the traditional pharmaceutical field. In the digital therapeutics space, it aims to establish new revenue-generating businesses and anticipates having three revenue-generating products on the market by 2021.